Trial Profile
Safety and efficacy of nilotinib in patients with chronic myeloid leukemia: A phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2016
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Step Stop trial
- 30 Aug 2016 New trial record
- 01 Aug 2015 Recruitment completed, according to results presented at the 21st Congress of the European Haematology Association.